Aprea Therapeutics, Inc.
APREHealthcare|Biotechnology|US
$0.52
+0.02 (+4.50%)
DCF Value
$2.14
Tangible Book / Share
$0.64
Cash / Share
$0.71
Clinical Trials (16)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06260514 Study of APR-1051 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | P1 | Recruiting | 90 | Open-label | APR-1051 |
| NCT03745716 APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) | MDS | P3 | Completed | 154 | RCT, Open-label | APR-246 + azacitidine, Azacitidine |
| NCT03391050 A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma | Melanoma | P1P2 | Terminated | 3 | Open-label | APR-246, Dabrafenib |
| NCT04383938 Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | Bladder Cancer, Gastric Cancer | P1P2 | Completed | 40 | Open-label | APR-246 (eprenetapopt) + Pembrolizumab |
| NCT03268382 p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 | High-grade Serous Ovarian Cancer | P2 | Completed | 36 | Open-label | APR-246, Pegylated Liposomal Doxorubicin Hydrochloride (PLD) |
| NCT04419389 APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) | Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | P1P2 | Terminated | 1 | Single-blind | APR-246 (eprenetapopt) + Acalabrutinib in CLL, APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL, APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT, APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT |
| NCT03931291 APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant | Acute Myeloid Leukemia or Myelodysplastic Syndromes | P2 | Completed | 33 | Open-label | APR-246 |
| NCT04905914 Study Of ATRN-119 In Patients With Advanced Solid Tumors | Advanced Solid Tumor | P1P2 | Completed | 43 | Open-label | ATRN-119 |
| NCT02098343 p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 | Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 | P1P2 | Completed | 247 | RCT, Open-label | APR-246, Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) |
| NCT07578467 Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs | HPV Positive Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma | P1P2 | Not Yet Recruiting | 35 | Open-label | ATRN-119 |
| NCT03072043 Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms | Myelodysplastic Syndrome, Acute Myeloid Leukemia | P1P2 | Completed | 55 | Open-label | APR-246, Azacitidine |
| NCT03588078 Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine | Myelodysplastic Syndrome With Gene Mutation, Acute Myeloid Leukemia With Gene Mutations | P1P2 | Completed | 53 | Open-label | APR-246, Azacitidine |
| NCT07617363 ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS | Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome | P1 | Not Yet Recruiting | 36 | Open-label | ATRN-119, Decitabine |
| NCT00900614 Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer | Hematologic Neoplasms, Prostatic Neoplasms | P1 | Completed | 36 | Open-label | APR-246 |
| NCT04638309 APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) | MDS, Myelodysplastic Syndromes | P1 | Terminated | 4 | Open-label | APR-548 + Azacitidine |
| NCT04214860 APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies | Myeloid Malignancy | P1 | Completed | 51 | Open-label | APR-246, Venetoclax, Azacitidine |